1. a) A Schedule I if the Department finds that:

   1. 1) the substance has high potential for abuse; and

      1. 2) the substance has no currently accepted medical use in treatment in the United States or lacks accepted safety for use in treatment under medical supervision [720 ILCS 570/203].

2. b) A Schedule II if the Department finds that:

   1. 1) the substance has high potential for abuse;

      1. 2) the substance has currently accepted medical use in treatment in the United States, or currently accepted medical use with severe restrictions; and
      2. 3) the abuse of the substance may lead to severe psychological or physiological dependence [720 ILCS 570/205].

3. c) A Schedule III if the Department finds that:

   1. 1) the substance has a potential for abuse less than the substances listed in Schedules I and II;
   2. 2) the substance has currently accepted medical use in treatment in the United States; and
   3. 3) abuse of the substance may lead to moderate or low physiological dependence or high psychological dependence [720 ILCS 570/207].

4. d) A Schedule IV if the Department finds that:

   1. 1) the substance has a low potential for abuse relative to substances in Schedule III;
   2. 2) the substance has currently accepted medical use in treatment in the United States; and
   3. 3) abuse of the substance may lead to limited physiological dependence or psychological dependence relative to the substances in Schedule III [720 ILCS 570/209].

5. e) A Schedule V if the Department finds that:

   1. 1) the substance has low potential for abuse relative to the controlled substances listed in Schedule IV;
   2. 2) the substance has currently accepted medical use in treatment in the United States; and
   3. 3) abuse of the substance may lead to limited physiological dependence or psychological dependence relative to the substances in Schedule IV, or the substance is a targeted methamphetamine precursor as defined in the Methamphetamine Precursor Control Act [720 ILCS 648]. [720 ILCS 570/211]

   4. f) Other Selected Drugs, including:

      1. 1) those medications that may contribute to clinical reviews of scheduled medications;
      2. 2) those medications determined to need additional monitoring or to assist in facilitating medication optimization and utilization; and
      3. 3) the dispensing of Naloxone for opioid overdose prevention.

For tracking purposes, the Department, upon recommendation of the PMPAC, may designate and list drugs, other substances, and immediate precursors as:

(Source: Amended at 47 Ill. Reg. 13500, effective September 8, 2023)